Show the Working

Increase NHS Spending and Workforce

Conservative · what the evidence says

An independent, source-checked look at Conservative’s policy “Increase NHS Spending and Workforce” — what it would actually do across the things that affect your life. Every claim below quotes the source behind it. How this works.

Public finances & the next generation — Hurts

moderate · moderate confidence

The policy promises above-inflation NHS spending rises every year with no stated funding mechanism; the IFS estimates meeting this commitment would require tax rises on the scale of adding roughly 7 percentage points to VAT. Without those rises, the spending path worsens the debt trajectory.

The evidence

Biggest unknown: Whether the productivity and workforce efficiency gains materialise at the scale needed to reduce the real cost of the commitment — if 2% annual productivity improvements are achieved, the net fiscal cost falls significantly.

Our reading: The policy commits to above-inflation NHS spending increases every year without specifying any funding mechanism. The IFS projects this path reaches an additional £50 billion by 2036-37 in real terms — a scale requiring either substantial tax increases (VAT up to 27%, or income tax up by 6pp) or equivalent borrowing. Neither route is set out in the policy text. Absent a credible funding source, this trajectory worsens the debt path and passes a growing debt-interest burden to future taxpayers — the core criterion under O12. The policy's own rationale for fiscal sustainability rests on productivity gains through technology and workforce expansion. But the IFS and NHS itself estimate 1.5–2% annual productivity improvements would be needed, which is well above the NHS's historical track record. If productivity gains fail to materialise at that scale, the unfunded spending gap widens further. The Nuffield Trust's view that no major party's NHS spending plan is credible reinforces that the ambition outpaces realistic financing. The policy does not borrow to invest in productive capacity in a way that clearly raises future output sufficient to service the debt — it funds ongoing consumption of healthcare services, which, while valuable, does not generate a direct fiscal return to offset borrowing costs. Counterfactually, absent the policy, NHS spending might grow more slowly, reducing short-term fiscal pressure but risking deteriorating health outcomes with their own long-run fiscal costs. However, no cited evidence quantifies this sufficiently to offset the primary worsening signal on the debt path. The magnitude is moderate rather than major because the time horizon is long (effects accumulate by 2036-37) and the financing gap, while large, is not unprecedented in UK fiscal history.

Healthcare — Mixed picture

moderate · moderate confidence

This policy promises more NHS spending, staff, and community services that could meaningfully improve access — but credible analysts warn the spending may not keep pace with demand, workforce targets face serious feasibility hurdles, and productivity gains assumed are historically unprecedented. Some elements like Pharmacy First are already showing real impact, while others like CDCs have not yet cut waiting times.

The evidence

Biggest unknown: Whether the stated spending increases are large enough to match rising demand, and whether workforce recruitment targets can be achieved without unrealistic surges in training enrolments and immigration.

Our reading: The policy combines three levers — spending, workforce, and service redesign — each of which has genuine upside potential but also material credibility gaps. On spending: the above-inflation commitment sounds substantial, but the Nuffield Trust's chief executive explicitly labels all three main parties' plans as incompatible with maintaining NHS capacity, and the IFS quantifies the fiscal mountain required to sustain such growth. The stated commitment may therefore not translate into delivered real-terms expansion sufficient to close demand gaps. On workforce: the recruitment targets (92,000 nurses, 28,000 doctors) nominally align with the NHS Long Term Workforce Plan, but training pipeline analysis shows meeting those numbers would require transformative — arguably unrealistic — shifts in undergraduate enrolment. Retention compounds supply-side risk: over half of leavers quit voluntarily, 43% are dissatisfied with pay, and the BMA warns pledges fall flat without retention plans. On service redesign: Pharmacy First is a concrete, already-operational success — 2.4 million consultations, 8% GP referral rate, broad sign-up. This genuinely relieves some primary care pressure. CDCs have expanded diagnostic activity by 6–10% but have not demonstrably cut waiting times, partly because demand rises to meet supply and staffing is drawn from existing trusts. Technology productivity gains are illustrated by pilots but require the NHS to achieve 1.5–2% annual productivity growth, historically unprecedented. On balance, this is a mixed verdict. Some real incremental improvements to access are visible (Pharmacy First) or plausible (CDCs, technology), but the headline spending and workforce commitments face serious credibility challenges from independent institutional analysis, and the productivity assumptions underwriting the whole plan are extremely ambitious. The net effect is real but uncertain improvement, with meaningful risk that demand growth and implementation challenges dilute or negate gains.